Pharmaceutical Pellets Market Opportunities Report to 2033: Competitive Landscape and Company Profiles
20 août 2024 12h31 HE
|
Research and Markets
Dublin, Aug. 20, 2024 (GLOBE NEWSWIRE) -- The "Pharmaceutical Pellets Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.The global...
Specialty Pharma Market Report 2024-2034: Specialty Pharmaceutical Market Surges in Global Spending Landscape
15 août 2024 05h33 HE
|
Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Specialty Pharma Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Specialty Pharma Market is set to...
Pharmaceutical Industry Net Zero Strategies Thematic Intelligence Report: Reduction Targets, Data, and Strategies of 18 Leading Pharmaceutical Companies
06 août 2024 10h11 HE
|
Research and Markets
Dublin, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The "Thematic Intelligence: Net Zero Strategies in the Pharmaceutical Sector" report has been added to ResearchAndMarkets.com's offering. This report...
Corporate Reputation of Pharma in 2023/2024: The Patient Perspective and Views of 2,500+ Patient Groups - Pharma Corporate Reputation Falls from COVID Highs
26 juin 2024 06h51 HE
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2023/2024: The Patient Perspective (Global Edition) - The Views of 2,500+ Patient Groups Worldwide" report has...
Survey Results of 830+ Patient Groups on the Pharmaceutical Industry and Environmental, Social, and Governance (ESG) Practices
24 juin 2024 11h44 HE
|
Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Pharma and ESG: The Patient Perspective, 2023 - The Views of 832 Patient Groups from Around the World" report has been added to ...
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
11 juin 2024 08h20 HE
|
Processa Pharmaceuticals, Inc.
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses...
Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034: Rising Opportunities for IBD Drugs in Asian Markets
31 mai 2024 06h32 HE
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Inflammatory...
Global Pharmaceutical Industry Outlook 2024: Key Growth Opportunities in Scaling Precision Oncology in Asia-Pacific Through Public-private Partnership Models
27 mai 2024 04h33 HE
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Global Pharmaceutical Industry Outlook, 2024" report has been added to ResearchAndMarkets.com's offering.The leading trends shaping the global...
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
06 mai 2024 08h00 HE
|
Processa Pharmaceuticals, Inc.
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Global Migraine Drugs Market Report 2024, By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants), By Route of Administration (Oral, Injectable) and By End-User
06 mai 2024 04h05 HE
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Migraine Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The migraine drugs market size has grown strongly...